News

How AI Is Unlocking New Biological Pathways and Therapies

Key Drivers of AI Drug Discovery

Where AI Meets Genetics: Accelerating Small Molecule Drug Development

Empress Therapeutics Turns to Human Microbiome to Uncover Targeted Therapies

Translating the Code of Life into Small Molecule Medicines

10 Startups to Watch: Empress Therapeutics Mines Microbial Genomes for Drugs

Metagenomics Revolution: Empress Therapeutics on Drug Discovery Breakthroughs

Emerging Company Profile: Empress Looks To The Body’s Internal Chemistry For Drug Leads

A Bet That the Next Blockbuster May Already Be Inside You

Editor's Pick: Empress Therapeutics

Why Empress Therapeutics Is Mining the Human Metagenome for Novel Therapies

AI-Driven Drug Discovery Straddles the Virtual and the Real

Applying Genetics to Chemistry to Find New Small Molecules

Sourcing Chemistry from Inside Humans

Empress Builds Base for Small-Molecule Innovation

Empress Therapeutics Named a PM360 2023 Innovative Startup

Finding Small Molecule Drugs Encoded in DNA

Harnessing Human Genetics to Discover Co-evolved Small Molecule Medicines

AI in Action Podcast: Jason Park, CEO at Empress Therapeutics

Raising Biotech Podcast: Empress Therapeutics Featuring Jason Park and Jim Collins

Decoding the Genetic Programmes: the Power of Artificial Intelligence

Flagship startup Empress Therapeutics launches to search for small molecule drug leads in microbial DNA

Flagship Startup Emerges to Find Drugs in Promising Hunting Ground—Our Bodies

Flagship-launched Empress aims to be a small molecule speedster, with up to 4 INDs over next 2 years

Flagship's newest startup has an ex-J&J immunologist as head scientist